



JUN 1 2004

Patent
Attorney's Docket No. 016800-438

FBI CENTER 1600/2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
De Lacharriere, Olivier et. al.)	Group Art Unit: 1617
Application No.: 09/841,078)	Examiner: Lauren Wells
Filed: April 25, 2001)	Confirmation No.: 6852
For: Use of a Histamine Antagonist, An)	
Interleukin-1 Antagonist And/Or A TNF)	
Alpha Antagonist In A Cosmetic,)	
Pharmaceutical Or Dermatological)	
Composition and Composition Obtained)	

DECLARATION UNDER 37 C.F.R. §1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Jean-Claude Yadan hereby states as follows:

- 1) I was awarded a Doctorate in Bio-organic Chemistry from the University of Sciences (Paris VI) in Paris, France in 1983.
- 2) Currently I am CEO at Tetrahedron SAS, a new Medicinal Chemistry Company.
- 3) My curriculum vitae, research experience and list of publications are attached hereto as Appendix I.
- 4) I am aware that the Examiner in the above-identified application has concluded that claims 19-20 and 23-37 contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. I respectfully disagree with this conclusion.
- 5) I have reviewed the specification of the above-identified patent application. Based on 20 years of research in the Medicinal Chemistry field, it is my professional opinion that one of ordinary skill in the art, having read the specification, would have been enabled to make and/or use the invention defined in claims 19-20 and 23-37 without engaging in undue experimentation. That is, before the effective filing date of the above-identified patent application, those of ordinary skill in the art were familiar with IL-1 and TNF-alpha antagonists. In addition, the specification's disclosure of IL-

1 and TNF-alpha antagonists with varying chemical structures clearly conveys to those of ordinary skill in the art that any compound that exhibits IL-1 and/or TNF-alpha antagonist activity, regardless of its chemical structure, can be used in the claimed invention. It is evident that the application describes the compounds in a functional manner (i.e., in terms of the compounds' antagonist activity) because it is the compounds' functional characteristics, and not their chemical structures, which make the compounds suitable for use in the claimed compositions. In my opinion the terms "IL-1 antagonist" and "TNF-alpha antagonist" are the most appropriate terms to define the compounds employed in the claimed compositions. These compounds cannot be more precisely defined in the application without unduly restricting the scope of the pending claims. Therefore, it is my professional opinion that one of ordinary skill in the art having read the instant specification and being aware of the various well-known IL-1 and TNF-alpha antagonist compounds, would be able to practice the claimed invention without undue experimentation.

6. To support my opinion, I have conducted a search for technical references that show that IL-1 and TNF-alpha antagonist compounds were well-known and readily-identifiable before the above-identified patent application was filed.

First of all, concerning IL-1, it has been shown, in 1984, that cyclosporine therapy inhibits *in vivo* IL-1 release during the inductive phase (e.g. the 7-day treatment) (1). However, Bochner *et al.* describe the treatment of human lung fragments *in vitro* with dexamethasone or hydrocortisone resulting in dose dependent inhibition of IL-1 production (2). It has been confirmed in monocyte-like tumor cell line where 10nM of dexamethasone suppress totally IL-1 synthesis (3). In 1989, Gilbertsen *et al.* showed that CI-949, an anti-allergy compound, is a weak inhibitor of IL-1 release from human peripheral blood lymphocytes (4). At the same time, it has been evidenced that hydroquinone inhibits macrophage production of IL-1 (5). Probulcol, a NSAID, inhibits the IL-1 secretion from macrophages (6). Schnyder *et al.* experienced IX 207-887, a novel antiarthritic agent, showing that it is a good inhibitor of IL-1 release from monocytes (7). Plasminogen activator inhibitors may constitute a negative feedback pathway on monocytes-macrophage IL-1 release and subsequent immune activation *in vivo* (8). In 1991, Sawada *et al.* evidenced that FK506, an immunosuppressive agent, is effective as an inhibitor of non-Tcell response *in vitro* and affects not only IL-1 release but also IL-1 synthesis (9). Moreover, pentamidine, an aromatic diamidine used to treat pneumonia, induced inhibition of IL-1 via an alteration in the post-translational modification of the protein (10). Pyridazinones derivatives showed as good inhibitors of IL-1 release from mouse adherent macrophages (11). Naturally occurring IL-1 receptor antagonist has been shown to block IL-1 biological actions (12).

Concerning TNF α , incubation of human monocytes stimulated with LPS with misoprostol resulted in a reduction of IL-1 and TNF α production (13). Colchicine, a natural microtubule depolymerizing agent, caused a decrease in TNF α biosynthesis through the TNF α mRNA decreased production (14). Moreover, treatment of challenged mice with cyclosporin A led to an abrogation of IL-1 and TNF α releases (15). Erythromycin as well as roxithromycin inhibited TNF α release from human monocytes stimulated by LPS in a dose-dependent manner (16). Probhakar *et al.* have shown that

pentoxifylline, a methylxanthine derivative, selectively inhibited LPS-induced TNF α release. SF&F 86002, an inhibitor of 5-LO and CO in arachidonic metabolism, inhibited LPS-induced release of TNF α and IL-1 by two order magnitude more than pentoxifylline (17). Beta-glucan blocked the secretion of TNF α induced by bacterial LPS (18). Moreover, chloroquine reduced TNF α release from macrophage by disrupting TNF α gene transcription (19). Corticosteroids treatment of AIDS patients led to significantly less TNF α release from LPS-stimulated alveolar macrophages (20). Azelastine, a potent antiallergic agent, inhibited in a dose-dependent manner the TNF α production (21). Isoproterenol, a beta-agonist, rolipram, a PDE-IV inhibitor, and IBMX, a non-selective PDE inhibitor, significantly inhibited TNF α release in the LPS stimulated human whole blood (22). Theophylline suppressed the TNF α release by blood monocytes and alveolar macrophages as shown by Spatafora et al. (23). Quinine specifically blocked TNF α production of human alveolar macrophages at the level of gene transcription (24).

In summary, natural or synthetic low molecular-weight compounds as well as biological macromolecules were known to inhibit release or production or to antagonize the effects of IL-1 and/or of TNF α . All these data were available to those of ordinary skill in the art before december 1994.

7 The following references (1-24) show that IL-1 and TNF-alpha antagonist compounds similar to those disclosed in the instant specification were well-known before the application filing date. Copies of these references are attached hereto in Appendix II. In addition, the specification discloses tests, which are suitable for identifying compounds as IL-1 and TNF-alpha antagonists.

8. Based on my professional experience, and in view of the above-identified references, I believe that a person of ordinary skill in the art, having read the specification of the above-identified patent application, would have been readily able to identify compounds as IL-1 and TNF-alpha antagonist, and, thus, would have been enabled to make and/or use the invention defined in claims 19-20 and 23-37 without undue experimentation.

Declaration By Inventor Under 37 C.F.R. § 1.132

Application No. 09/841,078Attorney's Docket No. 016800-438

Page 4


I HEREBY DECLARE that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date:

May 19th 2004

(Name of Declarant)

Yasun J.C. [Signature]



APPENDIX I

Curriculum Vitae, Research Experience and List of Publications

Jean-Claude YADAN, PhD.

Tel: (33) 06 61 32 13 06

email:jcyadan@aol.com

14, rue des Meuniers
93100-Montreuil France

JUN 1 2004

15 JUN 1600/2000

Background:

1983 PhD in Bio-organic Chemistry (Paris VI University)
1980 Master in Organic Chemistry (Paris VI University)

Professional Skills:

☐ *as scientific researcher*

1979-1980 junior researcher at ENS/CNRS (*Prof. D. MANSUY*).
1981-1983 researcher at CERCOA/CNRS (*Prof. F. LEGOFFIC*)
1984-1989 Head of chemistry laboratory/ Pharmaceutical Dept. of Research
Center Roussel-UCLAF (Romainville, France).
1990-1991 Head of chemistry laboratory in Research Center
Bioxytech SA (Bonneuil/Marne, France).
1991-1995 Head of Chemistry Research Dept.
Bioxytech SA / OXIS Int. SA (Bonneuil/Marne, France).
1995-1998 Scientific Director of Research Center
OXIS Int. SA (Bonneuil/Marne, France).
1998-2000 Scientific and Technical Director
Analytics Biophysics International SA (A.B.I.)
2001- Scientific Director of Expertise and Consulting SARL

☐ *as manager*

1989-1990 Funding of Bioxytech SA (Bonneuil/Marne, France) with 22
employees and 1500m²-area labs.
1990-1995 Manager of 8 researchers team
1996-1998 CEO, Directory Member,
1998-1999 Funding of Analytics Biophysics International SA
1999-2000 CEO, CA Member
2001- CEO of Expertise and Consulting SARL
2003- President of TETRAHEDRON SAS

- List of Scientific Publications -

Yadan, Jean Claude; Gonneau, Martine; Sarthou, Pierre; Le Goffic, François
« Sensitivity to nikkomycin Z in *Candida albicans*: role of peptide permeases »,
 J. Bacteriol.; 160 (3), 884-888 (1984).

Gonneau, M.; Yadan, J.C.; Sarthou, P.; Le Goffic, F.
« Nikkomycin Z as inhibitor of *Candida albicans* growth »,
 In: Chitin Nat. Technol., [Proc. Int. Conf. Chitin Chitosan], 3rd Meeting; Muzzarelli, R. A.; Jeuniaux, C.; Gooday, G. W., Eds., Plenum, New York, pp. 203-205 (1985).

Nébot, C.; Moutet, M.; Huet, P.; Xu, J.; Yadan, J.C. and Chaudière J.
« Spectrophotometric Assay of Superoxide Dismutase Activity Based on the Activated Autoxydation of a Tetracyclic Catechol »,
 Anal. Biochem.; 214, 442-451 (1993).

Chaudière J, Moutet M, Monnier D, Duport JM, Lemainque A and Yadan JC
« Measurement of alteration markers and protective systems »,
 Annales de Biologie Clinique; 51: 233 (1993).

Chaudière, J.; Yadan, J.C.; Erdelmeier, I. and Moutet, M.;
« Design of new selenium-containing mimics of glutathione peroxidase »
 In: Oxidative Processes and Antioxydants; Paoletti et al. Eds; Raven Press Ltd., New York; pp 165-184 (1994).

Chaudière, J.; Yadan, J.C.; Erdelmeier, I.; Tailhan-Lomont, C. and Moutet, M.;
« Nouveaux catalyseurs organosélénés mimant l'activité de la glutathion peroxydase »
 C.R. Soc.Biol.; 188; 283-304 (1994)

Xu, J.; Yadan, J.C.
« A new and convenient method for the synthesis of imidazole-2-thiones »,
 Synlett; 239 (1995).

Xu, J.; Yadan, J.C.
« Synthesis of L-(+)-ergothioneine »,
 J.Org.Chem.; 60 (20), 6296-6301 (1995).

Xu, J.; Yadan, J.C.
« First synthesis of (+)-Brazilane from (+)-Brazilin »,
 Tetrahedron Letters; 37 (14); 2421-2424 (1996)

Coutelle, C.; Lindenbaum, A.; Beeleville-Nabet, F.; Nicolas, MB.; Wellman, M.; Yadan, JC.; Leroy, P.

« **Méthodes de dosage du glutathion dans les milieux biologiques** »

Option/Bio; Supplément au n°170; 1-11 (1996)

Xu, J.; Yadan, J.C.

« **Synthesis of catechol derivatives: 5H-6, 6a, 7, 11b-tetrahydrobenzo[c]fluorene-3, 9, 10-triol** »,

submitted to Tetrahedron; (1997)

Yadan, JC.; Aguni, N.; Chaudière, J.;

« **Colorimetric Method of Measurement of Glutathione** »

in preparation, Method in Enzymology; (1997)

Chaudière, J.; Erdelmeier, I.; Moutet, M. and Yadan, JC.

« **One- versus two-electron transfers: Cytotoxic and cytoprotective effects of seleno-organic catalysts** »

submitted to Sulfur, Selenium and Tellurium Chemistry; (1998)

Gerard-Monnier, D.; Erdelmeier, I.; Regnard, K.; Moze-Henry, N.; Yadan, JC. and Chaudière, J.

« **Reactivity of N-methyl-2-phenylindole with malondialdehyde and 4-hydroxy-alkenals- Part I: Application to a colorimetric assay of lipid peroxidation** »

submitted to Chemical Research in Toxicology; (1998)

Erdelmeier, I.; Gerard-Monnier, D.; Yadan, JC. and Chaudière, J.

« **Reactivity of N-Methyl-2-Phenylindole with malondialdehyde and 4-hydroxy-alkenals- Part II: Mechanistic aspects of the colorimetric assay of lipid peroxidation products** »

submitted to Chemical Research in Toxicology; (1998)

Erdelmeier, I. and Yadan, JC.

« **New method to introduce selenium atom in phenyl ring** »

in preparation (1998)

- List of Scientific Communications -

Chaudière J, Gérard-Monnier D, Moutet M et Yadan JC;

« **Méthodes analytiques: Quantification des systèmes de protection antioxydante et de la peroxydation des lipides** »,

Journée de formation I.S.P.B. "Radicaux libres", Lyon, 1991.

Yadan, JC.; Aguini, N.; Chaudière, J.;

« **Specific and non-enzymatic determination of Glutathione in biological mixtures of Mercaptans** »;

Symposium on Free Radicals - Institut Pasteur - Paris - France, 1992.

Yadan, JC.; Aguini, N.; Chaudière, J.;

« **Fast and specific colorimetric assay of mercaptans with non-enzymatic discrimination of Glutathione** »;

in Free Radicals: From Basic Science to Medicine - Int. Soc. for Free Rad. Research - Turin, Italy; 1992.

Yadan, JC.; Antoine, M.; Aguini, N.; Tailhan, C.; Chaudière, J.;

« **Mercaptopyridine and Mercaptoquinoline from specific β -elimination of Glutathione Thioethers** »

International Symposium on the Organic Chemistry of Sulfur (ISOCS 15) - Caen - France; 1992.

Yadan, JC.; Moutet, M.; Nebot, C.; and Chaudière, J.;

« **Superoxide Dismutase Activity: Measurement and Relationship with Glutathione** »

Microalgae and Health - 1st European Symposium - Montpellier - France; 1993.

Gerard-Monnier, D.; Erdelmeier, I.; Regnard, K.; Moze-Henry, N.; Yadan, JC. and Chaudière J.;

« **Fast and specific assay of enaldehydes by-products of lipid peroxidation based on the reactivity of substituted indoles** »

85th AOCS Annual Meeting; Atlanta, USA; May 1994.

Xu, J. and Yadan, J.C.;

« **New method for the preparation of 2-thio-imidazole: Total Synthesis of L-(+)-ergothioneine** »

16th International Symposium on the Organic Chemistry of Sulfur; Merseburg, July 1994.

Nebot, C.; Bonoroni-Adele, S.; Tariosse, L.; Moutet, M.; Xu, J.; Yadan, JC. and Chaudière J.;

« **Scavengers of Ferryl Myoglobin protect the isolated heart from post-ischemic reperfusion injury** »

Lipoprotein Oxidation and Atherosclerosis; Pavia, Italy; September 1994.

Moutet, M.; D'Alessio, P.; Yadan, JC.; Erdelmeier, I. and Chaudière, J.;

« **GSH peroxidase mimics and endothelial cells** »

William Harvey Research Conferences, London, England; October 1994.

Chaudière, J.; Yadan, JC.; Erdelmeier, I.; Tailhan-Lomont, C. and Moutet, M.;

« **Design of new selenium-containing mimics of glutathione peroxidase** »

International Symposium on Nutrition and Antioxidants; Cannes, France; 1994.

Chaudière, J.; Moutet, M.; Yadan, J.C. and Erdelmeier, I.
« Design of new glutathione peroxidase mimics for endothelial protection »
 2nd Winter Research Conferences; Les 2 Alpes; France; 1995

Gérard-Monnier, D.; Erdelmeier, I.; Moze-Henry, N.; Yadan, J.C. and Chaudière, J.
« The reaction of N-methyl-2-phenylindole with the enaldehydes: Application to a novel assay of lipid peroxidation »
 21st ISF World Congress; The Hague; Netherlands; 1995

Erdelmeier, I.; Chaudière, J. and Yadan, J.C.
« Copper(II) assisted mild and efficient synthesis of new Se-N-heterocycles: Facile access to a promising class of Gpx mimics »
 11th IUPAC International Conference on Organic Synthesis; Amsterdam, The Netherlands, July 1996

Moutet, M.; Giroud, C.; Marshall, J.J.; Robinson, K.A.; Yadan, J.C. and Chaudière, J.
« Protective Effects of the Glutathione Peroxidase Mimic BXT-51072 in Models of Inflammatory Stress »
 VIII Biennial Meeting of International Society for Free Radical Research; Barcelona, Spain; October 1996

Yadan, J.C., Xu, J., Appéré, G. and Aguin, N.
« Seleno-organic pro-oxidants as new anticancer drugs in hormone-dependent tumors »
 88th Annual Meeting of American Association for Cancer Research, San Diego, CA April 1997

Erdelmeier, I. and Yadan, J.C.
« Synthesis and Study of new seleno-organic mimics of glutathione peroxidase »
 213th American Chemical Society Meeting; San Francisco, CA; April 1997

Ziemniak, J.A.; Moutet, M.; Yadan, J.C. and Mir N.
« The Activity of a Novel Glutathione Peroxidase Mimic, BXT-51072, in Dextran sulfate-induced Inflammatory Bowel Disease »
 Annual Meeting of the American Gastroenterological Association and American Association for the Study of Liver Diseases; May 1997

Erdelmeier, I.; Tailhan-Lomont, C.; Moutet, M.; Yadan, J.C.
« Copper(II)-assisted Synthesis of new Se-N-Heterocycles and Study of their Activity as Mimics of Glutathione Peroxidase »
 VIIth International Conference on the Chemistry of Selenium and Tellurium; Vaalsbroek Castle-Aachen; July 1997

- Patents -

Title	Inventors	Country	Filing N°	Filing Date	Patent N°	Pending Date
1 Piégeurs de mercaptans, préparation	Yadan et al.	France	9 114 782	91.11.29	9 114 782	11.02.94
2 Procédé de dosage de l'activité SOD utilisant un composé autoxydable, nécessaire pour sa mise en oeuvre, composés autoxydables et leur préparation	Xu, Jinzhu; Yadan, JC; Moutet, M; Chaudière, J.	France; Germany UK Italy USA Japan	9 114 781 93 901 768.7 93 901 768.7 93 901 768.7 244 866 5-509 871	91.11.29 92.11.25 92.11.25 92.11.25 92.11.25 92.11.25	9114781 E692 12 334.2 E 0 625 209 E 0 625 209 5 543 298	23.12.94 17.07.96 17.07.96 17.07.96 06.08.96
3 Composés autoxydables, préparation	Xu et al.	France	9 202 082	92.02.24		
4 Procédés spectrophotométriques de dosage des mercaptans totaux, du glutathion réduit (GSH) et des mercaptans autres que le GSH dans un milieu aqueux, réactifs et nécessaires pour leur mise en oeuvre	Yadan, JC; Antoine, M; Chaudière, J.	France; Germany UK Italy USA Japan	9 115 868 93 902 331.3 93 902 331.3 93 902 331.3 695 705 5-511 476	91.12.20 92.12.15 92.12.15 92.12.15 92.12.15 92.12.15	9 115 868 E 643 698 E 643 698 E 643 698	23.06.95 05.03.97 05.03.97 05.03.97
5 Procédé de dosage colorimétrique du dialdéhyde malonique et des autres énaldehydes en tant qu'indices de peroxydation lipidique, nécessaires pour sa mise en oeuvre, indoles substitués utilisables dans ce procédé et leur préparation	Gerard-Monnier D, Erdelmeier I, Chaudière J, Yadan JC.	France Europe USA USA Australia Canada Japan	9 305 430 94 916 258.0 362 418 702 197 67 955/94 2 139 591 6-525 048	93.05.06 94.05.06 94.05.06 94.05.06 94.05.06 94.05.06 94.05.06	9 305 430	28.07.95

6	Nouveau Procédé de Préparation de l'ergothionéine	Yadan, JC et XU, J.	France	9 315 457	93.12.22	9 315 457	13.10.95
			Europe	94 920 514.0	94.06.27		
			USA	194 457	94.02.08	5 438 151	01.08.95
			Australie	71 276/94	94.06.27		
			Canada	2 143 419	94.06.27		
			Japan	7-502 528	94.06.27		
7	Utilisation de dérivés 2-mercapto-imidazole substitués en position 4 (ou 5) comme agents antioxydants, leur procédés de préparation et leurs applications en pharmacie, cosmétique ou alimentaire	Yadan, JC; Xu, J; Moutet, M; Chaudière, J.	France Europe USA Australie Canada Japan	9 315 637 95 904 589.9 507 329 13 204/95 2 156 490 7-517 809	93.12.24 94.12.22 94.12.22 94.12.22 94.12.22 94.12.22	9 315 637	24.05.96
8	Nouveaux composés de structure benzisoslén-azoline et -azine, leur procédé de préparation et leurs applications thérapeutiques	Erdelmeier, I; Chaudière, J; Moutet, M; Yadan, JC.	France Europe USA Canada Australie Japan	9 404 107 95 916 723.0 2 164 642 23 111/95 7-526 125	94.04.07 95.04.07 95.04.07 95.04.07 95.04.07 95.04.07	9 404 107	28.06.96
9	Utilisation de nouveaux composés sélénisés comme agents pro-oxydants	Xu, Yadan, Appéré et Chaudière J.	France USA	9 608 929	96.07.17		
10	Composés organosélénisés cycliques	Erdelmeier et al.	France	9 616 102	96.12.27		
11	Disélenures et sélénosulfures aromatiques	Tailhan-Lomont et al.	France	9 616 103	96.12.27		

APPENDIX II

(Technical References)

1. Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): a role for IL 3 in graft tolerance?
J Immunol. 1984 Nov;133(5):2582-6
Abbud-Filho M, Kupiec-Weglinski JW, Araujo JL, Heidecke CD, Tilney NL, Strom TB.
2. Interleukin 1 production by human lung tissue. II. Inhibition by anti-inflammatory steroids.
J Immunol. 1987 Oct 1;139(7):2303-7.
Bochner BS, Rutledge BK, Schleimer RP.
3. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells.
J Immunol. 1987 Dec 15;139(12):4129-34.
Knudsen PJ, Dinarello CA, Strom TB.
4. In vitro effects of the antiallergy compound, CI-949, on interleukin-1 and 2 release, and on mitogen and alloantigen responsiveness.
Agents Actions. 1989 Jun;27(3-4):303-5.
Gilbertsen RB, Cullinen KM, Wilburn DJ, Dong MK, Conroy MC.
5. Bone marrow stromal cell regulation of B-lymphopoiesis. II. Mechanisms of hydroquinone inhibition of pre-B cell maturation.
J Pharmacol Exp Ther. 1989 Aug;250(2):582-90.
King AG, Landreth KS, Wierda D.
6. Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties.
FASEB J. 1990 Apr 1;4(6):1645-53.
Ku G, Doherty NS, Schmidt LF, Jackson RL, Dinerstein RJ.
7. Inhibition of interleukin-1 release by IX 207-887.
Agents Actions. 1990 Jun;30(3-4):350-62.
Schnyder J, Bollinger P, Payne T.
8. Monocyte-macrophage release of IL-1 is inhibited by type-1 plasminogen activator inhibitors.
J Clin Lab Immunol. 1990 Oct;33(2):83-90.
Robson SC, Saunders R, Kirsch RE.
9. Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937.
Cell Immunol. 1991 Feb;132(2):285-94.
Keicho N, Sawada S, Kitamura K, Yotsumoto H, Takaku F.
10. Pentamidine: an inhibitor of interleukin-1 that acts via a post-translational event.
Toxicol Appl Pharmacol. 1991 Mar 1;107(3):555-61.
Rosenthal GJ, Corsini E, Craig WA, Comment CE, Luster MI.
11. 4-substituted-5-acetyl-2-methyl-6-phenyl-3(2H)pyridazinones as PGE2 and IL-1 release inhibitors from mouse adherent macrophages.
Pharmacol Res. 1994 May-Jun;29(4):367-72.
Dal Piaz V, Giovannoni MP, Ciciani G, Becherucci C, Parente L.
12. Expression of interleukin-1 receptor antagonist in human pituitary adenomas in vitro.
J Clin Endocrinol Metab. 1994 Dec;79(6):1857-63.
Sauer J, Arzt E, Gumprecht H, Hopfner U, Stalla GK.

13. Effects of the prostaglandin analogue misoprostol on inflammatory mediator release by human monocytes.

Agents Actions. 1991 Sep;34(1-2):30-1.

Widomski DL, Walsh RE, Baron DA, Hidvegi MI, Fretland DJ, Collins PW, Gaginnella TS.

14. Colchicine has opposite effects on interleukin-1 beta and tumor necrosis factor-alpha production.

Am J Physiol. 1991 Oct;261(4 Pt 1):L315-21.

Allen JN, Herzyk DJ, Wewers MD.

15. Murine hypersensitivity pneumonitis: a study of cellular infiltrates and cytokine production and its modulation by cyclosporin A.

Am J Respir Cell Mol Biol. 1992 Jan;6(1):68-74.

Denis M, Cormier Y, Laviolette M.

16. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro.

Ann Otol Rhinol Laryngol Suppl. 1992 Oct;157:16-20.

Iino Y, Toriyama M, Kudo K, Natori Y, Yuo A.

17. Inhibition of CD44, CD45 and LFA-3 mediated cytokine release from human monocytes by SK&F 86002 and pentoxifylline.

Int J Immunopharmacol. 1993 Feb;15(2):205-9.

Prabhakar U, Lipshutz D, Truneh A.

18. Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide.

Immunol Lett. 1993 Jul;37(1):19-25.

Hoffman OA, Olson EJ, Limper AH.

19. Chloroquine inhibits macrophage tumour necrosis factor-alpha mRNA transcription.

Immunology. 1993 Sep;80(1):122-6.

Zhu X, Ertel W, Ayala A, Morrison MH, Perrin MM, Chaudry IH.

20. Effect of corticosteroids on IL1 beta and TNF alpha release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia.

Chest. 1993 Sep;104(3):751-5.

Huang ZB, Eden E.

21. Inhibitory effect of azelastine, a potent antiallergic agent, on release of tumor necrosis factor-alpha from activated human peripheral blood mononuclear cells and U937 cells.

Exp Dermatol. 1993 Oct;2(5):231-5.

Hamamoto Y, Nagai K, Muto M, Asagami C.

22. The effects of anti-inflammatory and antiallergic drugs on the release of IL-1 beta and TNF-alpha in the human whole blood assay.

Agents Actions. 1993;39 Spec No:C70-2.

Hartman DA, Ochalski SJ, Carlson RP.

23. Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages.

Eur Respir J. 1994 Feb;7(2):223-8.

Spatafora M, Chiappara G, Merendino AM, D'Amico D, Bellia V, Bonsignore G.

24. Quinine inhibits production of tumor necrosis factor-alpha from human alveolar macrophages.

Am J Respir Cell Mol Biol. 1994 May;10(5):514-20.

Maruyama N, Kakuta Y, Yamauchi K, Ohkawara Y, Aizawa T, Ohrai T, Nara M, Oshiro T, Ohno I, Tamura G, et al.